Additional exclusivity for a cancer treatment could cost the public $3 billion, analyst says
Last week, the FDA granted additional exclusivity to Eagle Pharmaceuticals’ cancer medicine Treanda (bendamustine hydrochloride), a decision that effectively halts the introduction of generic versions of the injection until 2022, which one analyst said could cost the public $3 billion.
The decision by the FDA comes as the company’s other bendamustine hydrochloride product, known as Bendeka, won seven years of orphan drug exclusivity last summer because of a US district court win for the company against the FDA.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters